person · Reporting owner
Shannon John Patrick Jr
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XERIS PHARMACEUTICALS INCXERS · Entity 134906 | See Remarks | October 05, 2021 | October 05, 2021 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director · See Remarks | August 01, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XERIS PHARMACEUTICALS INC
Report date October 05, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 193,333 |
Reported balance
After 2021-10-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 70,496 · Balance 193,333 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-10-05 · Disposition to issuer · Disposed 193,333 · Balance 0 F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-02-03 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-10-05 · Disposition to issuer · Disposed 160,335 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5: These options are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-06-11 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-05 · Disposition to issuer · Disposed 25,136 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5: These options are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.93 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-10-05 · Disposition to issuer · Disposed 28,072 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F7: These options are early exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2028-05-15 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-10-05 · Disposition to issuer · Disposed 34,977 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F7: These options are early exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2029-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-10-05 · Disposition to issuer · Disposed 80,000 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2030-08-18 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-10-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax.
F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time.
F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
F5: These options are fully vested as of the date hereof.
F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
F7: These options are early exercisable.
Xeris Biopharma Holdings, Inc.
Report date August 01, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,898,933 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Tax withholding · Disposed 36,645 · Balance 2,898,933 F1: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2026 Filed Aug 21, 2026 20:23 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 36,645 | $8.08 | $296,091.60 |
DisclosureSEC source: 0001867096-26-000073 · wk-form4_1787343799.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,898,933 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 110,750 | $7.36 | $815,120.00 |
DisclosureSEC source: 0001553595-26-000004 · wk-form4_1770073996.xml · nonDerivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,935,578 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 111,621 | $7.36 | $821,530.56 |
DisclosureSEC source: 0001553595-26-000004 · wk-form4_1770073996.xml · nonDerivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,046,328 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 118,134 | $7.36 | $869,466.24 |
DisclosureSEC source: 0001553595-26-000004 · wk-form4_1770073996.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,157,949 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 23:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 639,639 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001553595-26-000004 · wk-form4_1770073996.xml · derivative · entry 5 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,639 Underlying: Common Stock · 639,639 shares Expires 2036-01-30 F3 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 23:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 478,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001553595-26-000004 · wk-form4_1770073996.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,276,083 F1 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,900 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · derivative · entry 7 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,100 Underlying: Common Stock · 2,900 shares Expires 2030-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person received the stock options on August 26, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,136 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · derivative · entry 6 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,136 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 64,265 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · derivative · entry 5 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,265 shares Expires 2027-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person received the stock options on February 4, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 2,900 | $3.94 | $11,426.00 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · nonDerivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,797,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 25,136 | $1.55 | $38,960.80 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · nonDerivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,794,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 64,265 | $1.55 | $99,610.75 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,769,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 24,907 | $7.08 | $176,256.88 |
DisclosureSEC source: 0001553595-26-000002 · wk-form4_1767741265.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,705,346 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.040 to $7.350, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 22:58 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 87,100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001553595-25-000004 · wk-form4_1763420330.xml · derivative · entry 5 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,265 Underlying: Common Stock · 87,100 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 22:58 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 87,100 | $1.55 | $135,005.00 |
DisclosureSEC source: 0001553595-25-000004 · wk-form4_1763420330.xml · nonDerivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,730,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 22:58 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,970 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001553595-25-000004 · wk-form4_1763420330.xml · derivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,365 Underlying: Common Stock · 8,970 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 22:58 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 23,242 | $7.46 | $173,401.59 |
DisclosureSEC source: 0001553595-25-000004 · wk-form4_1763420330.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,643,153 F1 · kind: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 22:58 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 8,970 | $1.55 | $13,903.50 |
DisclosureSEC source: 0001553595-25-000004 · wk-form4_1763420330.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,666,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 20:24 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 36,918 | $5.38 | $198,618.84 |
DisclosureSEC source: 0001867096-25-000124 · wk-form4_1754339089.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,657,425 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025. F2 · balance_after: These shares include 7,225 shares that were purchased on June 30, 2025, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Appreciation Right · Derivative | 600,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001867096-25-000026 · wk-form4_1738629606.xml · derivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2027-03-02 F3 · derivative.exercise_date: This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date. F4 · derivative.underlying: Upon exercise, the stock appreciation right will be settled in cash. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-25-000026 · wk-form4_1738629606.xml · nonDerivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,687,118 F2 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 110,750 | $3.56 | $394,270.00 |
DisclosureSEC source: 0001867096-25-000026 · wk-form4_1738629606.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,887,118 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 110,750 | $3.56 | $394,270.00 |
DisclosureSEC source: 0001867096-25-000026 · wk-form4_1738629606.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,997,868 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:43 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 39,443 | $3.61 | $142,389.23 |
DisclosureSEC source: 0001867096-25-000015 · wk-form4_1736286205.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,108,618 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Appreciation Right · Derivative | 300,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · derivative · entry 10 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-09-01 F12 · derivative.exercise_date: The award will vest in full on the two-year anniversary of the grant date. F13 · derivative.underlying_shares: Upon exercise, the Stock Appreciation Right will be settled in cash. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,419,612 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 11,037 shares that were purchased on June 30, 2024, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2024 Filed Jan 31, 2024 22:05 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-24-000017 · wk-form4_1706738697.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,158,575 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. Read SEC document |
| January 31, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 110,750 | $2.46 | $272,445.00 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 9 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,148,061 F3 · date: This transaction is being reported late due to administrative oversight. F11 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024. Read SEC document |
| January 29, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 22,150 | $2.66 | $58,919.00 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 8 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,258,811 F3 · date: This transaction is being reported late due to administrative oversight. F10 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024. Read SEC document |
| January 03, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 40,834 | $2.24 | $91,468.16 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 7 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,280,961 F3 · date: This transaction is being reported late due to administrative oversight. F9 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 22:58 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | PurchaseCommon Stock | 30,769 | $1.64 | $50,399.62 |
DisclosureSEC source: 0001867096-23-000145 · wk-form4_1700261903.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,408,575 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6250 to $1.6400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 31, 2023 Filed Feb 1, 2023 21:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-23-000024 · wf-form4_167528602235679.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,377,806 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 8,896 shares that were purchased on June 30, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 9,880 | $1.24 | $12,251.20 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 6 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,321,795 F3 · date: This transaction is being reported late due to administrative oversight. F8 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023. Read SEC document |
| January 29, 2023 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 23,414 | $1.26 | $29,501.64 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 5 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,331,675 F3 · date: This transaction is being reported late due to administrative oversight. F7 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023. Read SEC document |
| January 03, 2023 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 41,334 | $1.12 | $46,294.08 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,355,089 F3 · date: This transaction is being reported late due to administrative oversight. F6 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023. Read SEC document |
| January 31, 2022 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 7,497 | $2.11 | $15,818.67 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,396,423 F3 · date: This transaction is being reported late due to administrative oversight. F5 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022. Read SEC document |
| January 29, 2022 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 15,692 | $2.11 | $33,110.12 |
DisclosureSEC source: 0001867096-24-000145 · wk-form4_1722633763.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,403,920 F3 · date: This transaction is being reported late due to administrative oversight. F4 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 23:16 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-22-000008 · wf-form4_164142456918577.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,910 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 5,081 shares that were purchased on June 30, 2021 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 22:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | PurchaseCommon Stock | 60,000 | $2.10 | $126,000.00 |
DisclosureSEC source: 0001867096-21-000077 · wf-form4_163675512137122.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,829 F2 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.09 to $2.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | PurchaseCommon Stock | 40,000 | $2.09 | $83,500.00 |
DisclosureSEC source: 0001867096-21-000077 · wf-form4_163675512137122.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,829 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.08 to $2.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · derivative · entry 8 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2030-08-18 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · derivative · entry 7 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2029-01-31 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,977 | Not disclosed Strike: $12.50 | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · derivative · entry 6 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,977 shares Expires 2028-05-15 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F7 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,072 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · derivative · entry 5 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,072 shares Expires 2028-01-31 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F7 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,136 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · derivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,136 shares Expires 2027-06-11 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 160,335 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · derivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,335 shares Expires 2027-02-03 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerCommon Stock | 193,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:32 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerCommon Stock | 70,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039242 · doc4.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,333 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 8 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-18 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 7 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.